Tirzepatide · 3 min read
When a switch makes sense (plateau, tolerability, the head-to-head data), how prescribers sequence it, and the monthly price change at every provider that carries both molecules.
When a switch makes sense (plateau, tolerability, the head-to-head data), how prescribers sequence it, and the monthly price change at every provider that carries both molecules.
The semaglutide-to-tirzepatide switch became one of the most common conversations in obesity medicine after SURMOUNT-5 showed tirzepatide's 20.2% average loss against semaglutide's 13.7% head-to-head. It is a legitimate, routinely managed transition — with a right way to do it and a predictable effect on your bill.
Three situations dominate. A plateau on maximal semaglutide: if weight has been stable for months at 2.4 mg with adherence intact, the dual-agonist mechanism offers genuinely additional pharmacology rather than more of the same. Tolerability at the doses that work: some patients who cannot hold semaglutide's higher doses do better on tirzepatide, plausibly via GIP's attenuating effect on nausea signaling. And response mismatch: individual variation in these drugs is wide, and non-response to one is not non-response to the class. What a switch is not: a guaranteed upgrade. Averages moved; individuals vary.
There is no official conversion table, and clinicians do not map semaglutide doses onto "equivalent" tirzepatide doses. The common pattern is to finish the semaglutide week, then begin tirzepatide at a low-to-intermediate rung — often 2.5 or 5 mg rather than the ladder's top — and retitrate by response, since incretin-experienced patients frequently tolerate faster escalation than true beginners. Expect a few transition weeks where appetite suppression dips as one drug washes out (semaglutide's week-long half-life helps smooth this) and GI symptoms can briefly resurface as the new agent titrates. This is prescriber territory; the practical point is that the switch is ordinary, not exotic.
At providers carrying both molecules, the tirzepatide premium is explicit. NexLife: $145–$165 semaglutide to $215 tirzepatide (a $50–$70 step). Mochi: $178 all-in to $278 (+$100). IVIM: $149 to $278 all-in (+$129). ShedRx: $175–$249 to $199–$289 depending on term and tier. Found: identical $169 prepaid / $289 monthly for both — one of the few places the switch is free. Henry: $149–$179 to $349. TrimRx: $199 to $349. On brand, Wegovy's flat $349 becomes Zepbound's $299–$449 (cheaper for the starter month, $100 more at maintenance). Full both-molecule pricing lives in the database, and the clinical comparison in tirzepatide vs. semaglutide.
Switching is a medical decision. Bring your history — response, side effects, goals — to the prescriber who will manage the transition.
Yes. Prescribers typically complete the final semaglutide week, then start tirzepatide the following week at a low-to-intermediate dose (commonly 2.5–5 mg) and retitrate by response.
On trial averages, tirzepatide outperforms (20.2% vs 13.7% in SURMOUNT-5), and switch studies show additional loss in many plateaued patients — but individual results vary and a switch is not a guarantee.